CSN Login
Members Online: 13

You are here

Roche to share important oncology data at European Cancer Congress (ECC) including information on herceptin and TDM-1

dfd24
Posts: 91
Joined: Mar 2011

from http://www.biosciencetechnology.com/news/2013/09/roche-share-important-oncology-data-european-cancer-congress-ecc#.UkKMfijWFyM

Kadcyla:

  • Abstract #15: LATE BREAKING ABSTRACT T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. ECC media briefing September 28. Proffered papers session, Saturday, September 28, 13:03 – 13:15 in Hall 7.1

Herceptin SC:

  • Abstract #1759: Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study. Poster session, Saturday, September 28, 09:30 – 16:30 in Hall 4

callerid
Posts: 99
Joined: Dec 2012

Very interesting. Do you know where these will be published.

Thanks

dfd24
Posts: 91
Joined: Mar 2011

i think if you look  up

European Cancer Congress (ECC) in the coming month they should talk about the results. also if you put in a google alert  for Kadcyla and Herceptin SC then any information would be emailed to your gmail mail account ( you can sign up for one if you don't have one ). also looking up the TH3RESA STUDY should bring results.best,

danièle

goty2001
Posts: 72
Joined: Jul 2012

Thanks for posting.  Hope it's good data.

 

Everybody should ensure they get tested for HER2+

Subscribe to Comments for "Roche to share important oncology data at European Cancer Congress (ECC) including information on herceptin and TDM-1"